- Home
- NAMS vs IDYA Comparison
NAMS vs IDYA Comparison
Compare NAMS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | IDYA |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NAMS | IDYA |
|---|---|---|
| Price | $25.28 | $39.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $46.75 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.0M | 658.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.81 | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | $22,503,000.00 | ★ $218,710,000.00 |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $540.65 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $23.05 | $23.23 |
| 52 Week High | $42.21 | $42.68 |
Technical Indicators
Market Signals| Indicator | NAMS | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 56.57 |
| Support Level | N/A | $33.57 |
| Resistance Level | $28.87 | $39.93 |
| Average True Range (ATR) | 0.98 | 1.41 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 25.00 | 56.40 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.